Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $42.00 Consensus Target Price from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have received an average rating of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $42.00.

A number of equities research analysts have recently weighed in on the company. Truist Financial boosted their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Jefferies Financial Group upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and upped their price target for the company from $41.00 to $44.00 in a research note on Friday, June 7th. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, HC Wainwright upgraded Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Tuesday, July 30th.

Collegium Pharmaceutical Trading Up 0.3 %

NASDAQ COLL opened at $36.21 on Friday. Collegium Pharmaceutical has a 52 week low of $20.95 and a 52 week high of $40.95. The company has a 50 day moving average price of $33.57 and a 200 day moving average price of $34.96. The company has a quick ratio of 1.14, a current ratio of 1.21 and a debt-to-equity ratio of 1.98. The firm has a market cap of $1.18 billion, a PE ratio of 15.09 and a beta of 0.93.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. The business had revenue of $145.28 million for the quarter, compared to the consensus estimate of $143.94 million. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The business’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.13 earnings per share. As a group, sell-side analysts forecast that Collegium Pharmaceutical will post 5.73 EPS for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 56,807 shares of the company’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $33.98, for a total value of $1,930,301.86. Following the sale, the executive vice president now directly owns 105,902 shares of the company’s stock, valued at $3,598,549.96. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CFO Colleen Tupper sold 19,710 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total transaction of $674,279.10. Following the sale, the chief financial officer now owns 130,845 shares of the company’s stock, valued at approximately $4,476,207.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Scott Dreyer sold 56,807 shares of the business’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the completion of the transaction, the executive vice president now owns 105,902 shares of the company’s stock, valued at $3,598,549.96. The disclosure for this sale can be found here. Company insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in COLL. Pacer Advisors Inc. boosted its stake in shares of Collegium Pharmaceutical by 31.8% during the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after acquiring an additional 821,541 shares in the last quarter. Rubric Capital Management LP raised its holdings in Collegium Pharmaceutical by 27.2% in the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after purchasing an additional 499,473 shares during the period. Assenagon Asset Management S.A. boosted its position in Collegium Pharmaceutical by 411.1% during the second quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock worth $11,661,000 after purchasing an additional 291,286 shares in the last quarter. LSV Asset Management grew its holdings in Collegium Pharmaceutical by 188.7% in the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after purchasing an additional 248,751 shares during the period. Finally, New York State Common Retirement Fund grew its holdings in Collegium Pharmaceutical by 1,475.5% in the fourth quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock valued at $6,190,000 after purchasing an additional 188,347 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.